| Literature DB >> 19796866 |
Elizabeth W LaPensee1, Christopher R LaPensee, Sejal Fox, Sandy Schwemberger, Scott Afton, Nira Ben-Jonathan.
Abstract
Resistance to chemotherapy is a major problem facing breast cancer patients. Cisplatin, a highly effective DNA-damaging drug, has shown only little success in breast cancer treatment. We are reporting that low nanomolar doses of bisphenol A (BPA) or estradiol antagonize cisplatin cytotoxicity in breast cancer cells, with their effects not mediated via classical estrogen receptors. Although both compounds increase the expression of Bcl-2, a Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting those of estradiol. Blockade of BPA and E2 actions should sensitize ER-negative breast tumors to anti-cancer drugs and allow for the inclusion of cisplatin in treatment regimens. 2009 Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19796866 PMCID: PMC2853868 DOI: 10.1016/j.canlet.2009.09.005
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679